Catechol-o-methyltransferase val158met polymorphism and antisaccade eye movements in schizophrenia

Schizophrenia Bulletin

Volumn 36, Issue 1, 2010, Pages 157-164

  Haraldsson, Haraldur Magnus ^a   Ettinger, Ulrich ^b   Magnusdottir, Brynja B ^a,b   Sigmundsson, Thordur ^a   Sigurdsson, Engilbert ^a   Ingason, Andres ^c   Petursson, Hannes ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

Antisaccade; COMT val158met polymorphism; Dopamine; Endophenotype; Oculomotor; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE; VALINE;

ADULT; ARTICLE; CONTROLLED STUDY; EYE MOVEMENT; FEMALE; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFRARED OCULOGRAPHY; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ALLELES; AMINO ACID SUBSTITUTION; CATECHOL O-METHYLTRANSFERASE; DOPAMINE; FEMALE; FRONTAL LOBE; GENE DOSAGE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ISOENZYMES; MALE; METHIONINE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES; SACCADES; SCHIZOPHRENIA; VALINE; YOUNG ADULT;

EID: 73949106158     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn064     Document Type: Article

References (78)

1. Riley B, Kendler KS. Molecular genetic studies of schizophrenia. Eur J Hum Genet. 2006;14(6):669-680.
2. Axelrod J, Tomchick R. Enzymatic O-methylation of epi-nephrine and other catechols. JBiol Chem. 1958;233(3):702-705.
3. Gasparini M, Fabrizio E, Bonifati V, Meco G. Cognitive improvement during tolcapone treatment in Parkinson's disease. J Neural Transm. 1997;104(8-9):887-894.
4. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 1991;251(4996):947-950.
5. Weinberger DR, Egan MF, Bertolino A, et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry. 2001; 50(11):825-844.
6. Carlsson A. Historical aspects and future directions. In: Kapur S, ed. Dopamine in the Pathophysiology and Treatment of Schizophrenia. London: Taylor and Francis; 2003:1-13.
7. Craddock N, O'Donovan MC, Owen MJ. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull. 2006;32(1):9-16.
8. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransfer-ase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6(3):243-250.
9. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 2001;98(12):6917-6922.
10. Goldberg TE, Egan MF, Gscheidle T, et al. Executive sub-processes in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry. 2003;60(9):889-896.
11. Chen X, Wang X, O'Neill AF, Walsh D, Kendler KS. Variants in the catechol-o-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Mol Psychiatry. 2004;9(10):962-967.
12. Shifman S, Bronstein M, Sternfeld M, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet. 2002;71(6):1296-1302.
13. Chen CH, Lee YR, Chung MY, et al. Systematic mutation analysis of the catechol O-methyltransferase gene as a candidate gene for schizophrenia. Am J Psychiatry. 1999;156(8): 1273-1275.
14. Daniels JK, Williams NM, Williams J, et al. No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O-methyltransferase activity. Am J Psychiatry. 1996;153(2):268-270.
15. Karayiorgou M, Gogos JA, Galke BL, et al. Identification of sequence variants and analysis of the role of the catechol-O-methyl-transferase gene in schizophrenia susceptibility. Biol Psychiatry. 1998;43(6):425-431.
16. Munafo MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol Psychiatry. 2005; 10(8):765-770.
17. Calkins ME, Iacono WG. Eye movement dysfunction in schizophrenia: a heritable characteristic for enhancing pheno-type definition. Am J Med Genet. 2000;97(1):72-76.
18. Fukushima J, Fukushima K, Chiba T, Tanaka S, Yamashita I, Kato M. Disturbances of voluntary control of saccadic eye movements in schizophrenic patients. Biol Psychiatry. 1988; 23(7):670-677.
19. Hutton SB, Ettinger U. The antisaccade task as a research tool in psychopathology: a critical review. Psychophysiology. 2006;43(3):302-313.
20. Calkins ME, Curtis CE, Iacono WG, Grove WM. Antisac-cade performance is impaired in medically and psychiatrically healthy biological relatives of schizophrenia patients. Schiz-ophr Res. 2004;71(1):167-178.
21. Ettinger U, Picchioni M, Hall MH, et al. Antisaccade performance in monozygotic twins discordant for schizophrenia: the Maudsley twin study. Am J Psychiatry. 2006;163(3): 543-545.
22. Karoumi B, Ventre-Dominey J, Vighetto A, Dalery J, d'Ama-to T. Saccadic eye movements in schizophrenic patients. Psychiatry Res. 1998;77(1):9-19.
23. Klein C, Heinks T, Andresen B, Berg P, Moritz S. Impaired modulation of the saccadic contingent negative variation preceding antisaccades in schizophrenia. Biol Psychiatry. 2000; 47(11):978-990.
24. Thaker GK, Cassady S, Adami H, Moran M, Ross DE. Eye movements in spectrum personality disorders: comparison of community subjects and relatives of schizophrenic patients. Am J Psychiatry. 1996;153(3):362-368.
25. Thaker GK, Ross DE, Cassady SL, Adami HM, Medoff DR, Sherr J. Saccadic eye movement abnormalities in relatives of patients with schizophrenia. Schizophr Res. 2000;45(3): 235-244.
26. Ettinger U, Kumari V, Crawford TJ, et al. Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia. J Psychiatr Res. 2004;38(2):177-184.
27. Fukushima J, Fukushima K, Miyasaka K, Yamashita I. Voluntary control of saccadic eye movement in patients with frontal cortical lesions and parkinsonian patients in comparison with that in schizophrenics. Biol Psychiatry. 1994;36(1): 21-30.
28. Pierrot-Deseilligny C, Rosa A, Masmoudi K, Rivaud S, Gaymard B. Saccade deficits after a unilateral lesion affecting the superior colliculus. J Neurol Neurosurg Psychiatry. 1991; 54(12):1106-1109.
29. Everling S, DeSouza JF. Rule-dependent activity for prosac-cades and antisaccades in the primate prefrontal cortex. J Cogn Neurosci. 2005;17(9):1483-1496.
30. Funahashi S, Chafee MV, Goldman-Rakic PS. Prefrontal neuronal activity in rhesus monkeys performing a delayed anti-saccade task. Nature. 1993;365(6448):753-756. (Pubitemid 23339881)
31. McDowell JE, Brown GG, Paulus M, et al. Neural correlates of refixation saccades and antisaccades in normal and schizophrenia subjects. Biol Psychiatry. 2002;51(3):216-223.
32. O'Driscoll GA, Alpert NM, Matthysse SW, Levy DL, Rauch SL, Holzman PS. Functional neuroanatomy of antisaccade eye movements investigated with positron emission tomography. Proc Natl Acad Sci USA. 1995;92(3):925-929.
33. Sweeney JA, Mintun MA, Kwee S, et al. Positron emission tomography study of voluntary saccadic eye movements and spatial working memory. J Neurophysiol. 1996;75(1): 454-468.
34. Myles-Worsley M, Coon H, McDowell J, et al. Linkage of a composite inhibitory phenotype to a chromosome 22q locus in eight Utah families. Am J Med Genet. 1999;88(5):544-550.
35. Stefanis NC, Van Os J, Avramopoulos D, et al. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotypy but not cognition: a population study in 543 young men. Biol Psychiatry. 2004;56(7):510-515.
36. Haraldsson HM, Ettinger U, Magnusdottir BB, Sigmundsson T, Sigurdsson E, Petursson H. Eye movement deficits in schizophrenia: investigation of a genetically homogenous Icelandic sample. Eur Arch Psychiatry Clin Neurosci. [published online ahead of print April 24, 2008].
37. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35(6):773-782.
38. Spitzer R, Endicott J. The Schedule for Affective Disorders and Schizophrenia, Lifetime Version. 3rd ed New York, NY: NewYork State Psychiatric Institute; 1977.
39. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
40. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M. I. N. I. ): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:(suppl 20):22-33; quiz 34-57.
41. Rosa A, Peralta V, Cuesta MJ, et al. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry. 2004;161(6):1110-1112.
42. Clementz BA, McDowell JE, Zisook S. Saccadic system functioning among schizophrenia patients and their first-degree biological relatives. J Abnorm Psychol. 1994;103(2):277-287.
43. Nieman D, Becker H, van de Fliert R, et al. Antisaccade task performance in patients at ultra high risk for developing psychosis. Schizophr Res. 2007;95(1-3):54-60.
44. Crawford TJ, Puri BK, Nijran KS, Jones B, Kennard C, Lewis SW. Abnormal saccadic distractibility in patients with schizophrenia: a 99mTc-HMPAO SPET study. Psychol Med. 1996;26(2):265-277.
45. 158Met genotype is associated with BOLD response as a function of task characteristic. Neuropsychopharmacology. [published online ahead of print January 30, 2008].
46. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O- methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004;29(11):1943-1961.
47. Duka T, Lupp A. The effects of incentive on antisaccades: is a dopaminergic mechanism involved? Behav Pharmacol. 1997;8(5):373-382.
48. Jazbec S, McClure E, Hardin M, Pine DS, Ernst M. Cognitive control under contingencies in anxious and depressed adolescents: an antisaccade task. Biol Psychiatry. 2005; 58(8):632-639.
49. Enoch MA, Xu K, Ferro E, Harris CR, Goldman D. Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism. Psychiatr Genet. 2003; 13(1):33-41.
50. Woo JM, Yoon KS, Choi YH, Oh KS, Lee YS, Yu BH. The association between panic disorder and the L/L genotype of cat-echol-O-methyltransferase. J Psychiatr Res. 2004;38(4):365-370.
51. Karayiorgou M, Altemus M, Galke BL, et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci U S A. 1997;94(9):4572-4575.
52. Kirov G, Murphy KC, Arranz MJ, et al. Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiatry. 1998;3(4):342-345.
53. Li T, Vallada H, Curtis D, et al. Catechol-O-methyltransfer-ase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity al-lele with bipolar affective disorder. Pharmacogenetics. 1997;7(5):349-353.
54. Reuter M, Kirsch P, Hennig J. Inferring candidate genes for attention deficit hyperactivity disorder (ADHD) assessed by the World Health Organization Adult ADHD Self-Report Scale (ASRS). J Neural Transm. 2006;113(7):929-938.
55. Ohara K, Nagai M, Suzuki Y, Ohara K. Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression. Neuroreport. 1998;9(7):1305-1308.
56. Smyrnis N, Evdokimidis I, Stefanis NC, et al. Antisaccade performance of 1, 273 men: effects of schizotypy, anxiety, and depression. J Abnorm Psychol. 2003;112(3):403-414.
57. Rosenberg DR, Dick EL, O'Hearn KM, Sweeney JA. Response-inhibition deficits in obsessive-compulsive disorder: an indicator of dysfunction in frontostriatal circuits. J Psychiatry Neurosci. 1997;22(1):29-38.
58. Tien AY, Pearlson GD, Machlin SR, Bylsma FW, Hoehn-Saric R. Oculomotor performance in obsessive-compulsive disorder. Am J Psychiatry. 1992;149(5):641-646.
59. Katsanis J, Kortenkamp S, Iacono WG, Grove WM. Anti-saccade performance in patients with schizophrenia and affective disorder. J Abnorm Psychol. 1997;106(3):468-472.
60. Sereno AB, Holzman PS. Antisaccades and smooth pursuit eye movements in schizophrenia. Biol Psychiatry. 1995;37(6):394-401.
61. Goldman-Rakic PS, Muly EC, III, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev. 2000;31(2-3):295-301.
62. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: val158met and beyond. Biol Psychiatry. 2006;60(2):141-151.
63. Sutrala SR, GoossensD, Williams NM, etal. Genecopy number variation in schizophrenia. Schizophr Res. 2007;96(1-3):93-99.
64. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 2007;8(5):355-367.
65. Meyer-Lindenberg A, Nichols T, Callicott JH, et al. Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry. 2006;11(9):867-877, 797. (Pubitemid 44299108)
66. Polli FE, Barton JJ, Cain MS, Thakkar KN, Rauch SL, Manoach DS. Rostral and dorsal anterior cingulate cortex make dissociable contributions during antisaccade error commission. Proc Natl Acad Sci U S A. 2005;102(43):15700- 15705.
67. Weissman DH, Roberts KC, Visscher KM, Woldorff MG. The neural bases of momentary lapses in attention. Nat Neurosci. 2006;9(7):971-978.
68. Ungerleider LG, Courtney SM, Haxby JV. A neural system for human visual working memory. Proc Natl Acad Sci U S A. 1998;95(3):883-890.
69. McDowell JE, Myles-Worsley M, Coon H, Byerley W, Clementz BA. Measuring liability for schizophrenia using optimized antisaccade stimulus parameters. Psychophysiology. 1999;36(1):138-141.
70. Strous RD, Lapidus R, Viglin D, Kotler M, Lachman HM. Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia. Neurosci Lett. 2006;393(2-3):170-173.
71. Wonodi I, Mitchell BD, Stine OC, et al. Lack of association between COMT gene and deficit/nondeficit schizophrenia. Behav Brain Funct. 2006;2:42.
72. Strous RD, Nolan KA, Lapidus R, Diaz L, Saito T, Lachman HM. Aggressive behavior in schizophrenia is associated with the low enzyme activity COMT polymorphism: a replication study. Am J Med Genet B Neuropsychiatr Genet. 2003; 120(1):29-34.
73. Ohmori O, Shinkai T, Kojima H, et al. Association study of a functional catechol-O-methyltransferase gene polymorphism in Japanese schizophrenics. Neurosci Lett. 1998;243(1-3):109-112.
74. Rujescu D, Giegling I, Gietl A, Hartmann AM, Moller HJ. A functional single nucleotide polymorphism (V158M) in the COMT gene is associated with aggressive personality traits. Biol Psychiatry. 2003;54(1):34-39.
75. Fan JB, Zhang CS, Gu NF, et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol Psychiatry. 2005;57(2):139-144.
76. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltrans-ferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117-1127.
77. Nicodemus KK, Kolachana BS, Vakkalanka R, et al. Evidence for statistical epistasis between catechol-O-methyltrans-ferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum Genet. 2007;120(6):889-906.
78. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;10(1):40-68; image 45.